2-氧代-4-(3-吡啶基)-3-丁烯-1-酸 | 101714-03-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-氧代-4-(3-吡啶基)-3-丁烯-1-酸
• 英文名称: 2-oxo-4-(3-pyridyl)-3-butene-1-oic acid
• 英文别名: (E)-2-oxo-4-(pyridin-3-yl)but-3-enoic acid；2-oxo-4t-[3]pyridyl-but-3-enoic acid；2-Oxo-4t-[3]pyridyl-but-3-ensaeure；2-oxo-4-(pyridin-3-yl)-3-butenoic acid；(E)-2-oxo-4-pyridin-3-ylbut-3-enoic acid
• CAS: 101714-03-8
• 化学式: C₉H₇NO₃
• 分子量: 177.159
• InChiKey: ROXNESLCSLAKKG-ONEGZZNKSA-N

物化性质

• 沸点：
  342.4±34.0 °C(Predicted)
• 密度：
  1.343±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  67.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-氧代-4-(3-吡啶基)-3-丁烯-1-酸 在 palladium 10% on activated carbon 、 氢气 作用下， 以 异丙醇 为溶剂， 生成 2-oxo-4-(pyridin-3-yl)butanoic acid
  参考文献：
  名称：

  Analysis of Structure–Activity Relationships of Novel Inhibitors of the Macrophage Infectivity Potentiator (Mip) Proteins of Neisseria meningitidis, Neisseria gonorrhoeae, and Burkholderia pseudomallei

  摘要：

  DOI：

  10.1021/acs.jmedchem.3c00458
• 作为产物：
  描述：

  3-吡啶甲醛 在 盐酸 、 potassium hydroxide 作用下， 以 甲醇 为溶剂， 生成 2-氧代-4-(3-吡啶基)-3-丁烯-1-酸
  参考文献：
  名称：

  Analysis of Structure–Activity Relationships of Novel Inhibitors of the Macrophage Infectivity Potentiator (Mip) Proteins of Neisseria meningitidis, Neisseria gonorrhoeae, and Burkholderia pseudomallei

  摘要：

  DOI：

  10.1021/acs.jmedchem.3c00458

文献信息

• 1-dethia-2-thia-cephalosporanic acids
  申请人：Roussel Uclaf

  公开号：US05663164A1

  公开（公告）日：1997-09-02

  Novel 1-dethia-2-thia-cephalosporanic acid derivatives of the formula ##STR1## wherein R is selected from the group consisting of ##STR2## Ra is an organic radical, R.sub.i and R.sub.j are individually selected from the group consisting of hydrogen, aliphatic, aromatic and heterocycle or taken together with the nitrogen atom to which they are attached form an optionally substituted cycle or R.sub.b NH--, R.sub.b is optionally substituted carbocyclic or heterocyclic aryl, R.sub.1 and --COM are as defined in the specification, R.sub.4 is hydrogen or methoxy, n.sub.2 is 0, 1 or 2 and their non-toxic, pharmaceutically acceptable acid addition salts in racemic or optically active form having antibiotic activity and their preparation and novel intermediates.

  1-德西亚-2-硫代头孢菌素酸衍生物的新颖式样的分子式为##STR1## 其中R选自##STR2## Ra是有机基团，R.sub.i和R.sub.j分别选自氢、脂肪、芳香和杂环的群，或者与它们附着的氮原子一起形成一个可选取代的环，或者R.sub.b NH--，R.sub.b是可选取代的碳环或杂环芳基，R.sub.1和--COM如规范所定义，R.sub.4是氢或甲氧基，n.sub.2为0、1或2，它们的无毒、药用可接受的酸盐以拉丁或光学活性形式具有抗生素活性，并且它们的制备和新颖中间体。
• Iridium/f-Amphox-Catalyzed Asymmetric Hydrogenation of Styrylglyoxylamides
  作者：Jialin Wen、Xumu Zhang、Simin Wang、Yuena Yu

  DOI：10.1055/s-0037-1609623

  日期：2018.10

  We report an iridium-catalyzed asymmetric hydrogenation reaction for the preparation of chiral homophenylalanine derivatives. Catalyzed by an iridium/f-amphox complex, the asymmetric hydrogenation of styrylglyoxylamides was conducted smoothly with turnover numbers of up to 10,000 and up to 98% ee. This method was successfully applied in a synthesis of a fragment of benazepril, a drug used for the treatment

  我们报告了用于制备手性高苯丙氨酸衍生物的铱催化不对称氢化反应。在铱/f-amphox 络合物的催化下，苯乙烯基乙醛酰胺的不对称氢化顺利进行，转化率高达 10,000，ee 高达 98%。该方法已成功应用于苯那普利片段的合成，这是一种用于治疗高血压的药物。
• Non-Flushing Niacin Analogues, and Methods of Use Thereof
  申请人：Bachovchin William W.

  公开号：US20090312355A1

  公开（公告）日：2009-12-17

  One aspect of the present invention relates to substituted pyridines and pharmaceutically acceptable salts thereof that are active against a range of mammalian maladies. Another aspect of the invention relates to a pharmaceutical composition, comprising a compound of the present invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. The present invention also relates to methods of treating a range of mammalian maladies or conditions, including but not limited to hyperlipidemia, hypercholesterolemia, atherosclerosis, coronary artery disease, congestive heart failure, cardiovascular disease, hypertension, coronary heart disease, angina, pellagra, Hartnup's syndrome, carcinoid syndrome, arterial occlusive disease, obesity, hypothyroidism, vasoconstriction, osteoarthritis, rheumatoid arthritis, diabetes, Alzheimer's disease, lipodystrophy, or dyslipidemia, raising serum high-density lipoprotein (HDL) levels, and lowering serum low-density lipoprotein (LDL) levels.

  本发明的一个方面涉及取代吡啶及其药学上可接受的盐，对一系列哺乳动物疾病具有活性。本发明的另一个方面涉及一种制药组合物，包括本发明的化合物或其药学上可接受的盐，以及药学上可接受的载体。本发明还涉及治疗一系列哺乳动物疾病或病症的方法，包括但不限于高脂血症、高胆固醇血症、动脉粥样硬化、冠状动脉疾病、充血性心力衰竭、心血管疾病、高血压、冠心病、心绞痛、糙皮病、哈特努普综合征、类癌综合征、动脉闭塞性疾病、肥胖症、甲状腺功能减退症、血管收缩、骨关节炎、类风湿性关节炎、糖尿病、阿尔茨海默病、脂肪萎缩症或血脂异常，提高血清高密度脂蛋白（HDL）水平，降低血清低密度脂蛋白（LDL）水平。
• NON-FLUSHING NIACIN ANALOGUES, AND METHODS OF USE THEREOF
  申请人：Trustees of Tufts College

  公开号：US20160151343A1

  公开（公告）日：2016-06-02

  One aspect of the present invention relates to substituted pyridines and pharmaceutically acceptable salts thereof that are active against a range of mammalian maladies. Another aspect of the invention relates to a pharmaceutical composition, comprising a compound of the present invention or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient. The present invention also relates to methods of treating a range of mammalian maladies or conditions, including but not limited to hyperlipidemia, hypercholesterolemia, atherosclerosis, coronary artery disease, congestive heart failure, cardiovascular disease, hypertension, coronary heart disease, angina, pellagra, Hartnup's syndrome, carcinoid syndrome, arterial occlusive disease, obesity, hypothyroidism, vasoconstriction, osteoarthritis, rheumatoid arthritis, diabetes, Alzheimer's disease, lipodystrophy, or dyslipidemia, raising serum high-density lipoprotein (HDL) levels, and lowering serum low-density lipoprotein (LDL) levels.

  本发明的一个方面涉及取代吡啶及其药学上可接受的盐，对多种哺乳动物疾病具有活性。本发明的另一个方面涉及一种制药组合物，包括本发明的化合物或其药学上可接受的盐；以及药学上可接受的赋形剂。本发明还涉及治疗多种哺乳动物疾病或症状的方法，包括但不限于高脂血症、高胆固醇血症、动脉粥样硬化、冠状动脉疾病、充血性心力衰竭、心血管疾病、高血压、冠心病、心绞痛、糙皮病、哈特努普综合症、类癌综合症、动脉闭塞性疾病、肥胖症、甲状腺功能减退症、血管收缩、骨关节炎、类风湿性关节炎、糖尿病、阿尔茨海默病、脂肪萎缩症或血脂异常，提高血清高密度脂蛋白（HDL）水平，降低血清低密度脂蛋白（LDL）水平。
• Strell; Kopp, Chemische Berichte, 1958, vol. 91, p. 1621,1629
  作者：Strell、Kopp

  DOI：——

  日期：——